Regenxbio reiterated its financial guidance previously provided on May 8: REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $380.5M as of March 31, to fund its operations into 2026. This cash runway guidance is based on the Company’s current operational plans and excludes the impact of any payments that may be received from AbbVie upon the achievement of development or commercial milestones under our ABBV-RGX-314 collaboration, including a potential, one-time $200.0M milestone for achievement of first patient dosed in the first pivotal trial for suprachoroidal delivery for treatment of DR, and the potential monetization of a priority review voucher that may be received for RGX-121.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio initiated with a Buy at Goldman Sachs
- Regenxbio price target raised to $38 from $36 at H.C. Wainwright
- Regenxbio sees cash, cash equivalents, securities sufficient into 2026
- Regenxbio reports Q1 EPS ($1.38), consensus ($1.26)
- REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights